Treatment response and survival outcomes of ER-low versus ER-0 HER2-negative breast cancer after neoadjuvant chemotherapy: a multicenter real-world study

Background The clinical significance of ER-low tumors compared with ER-0 tumors in HER2-negative breast cancer remains poorly defined, particularly regarding response to neoadjuvant chemotherapy and survival outcomes. This study aimed to compare the clinical characteristics, treatment response, and survival outcomes between ER-low and ER-0 tumors in a real-world multicenter cohort. Methods We conducted a multicenter retrospective cohort study of patients with HER2-negative breast cancer who received neoadjuvant chemotherapy. Patients were categorized according to ER expression as ER-0 or ER-low (1–10%). The primary endpoint was pCR, while disease-free survival (DFS) and breast cancer-specific survival (BCSS) were evaluated as survival outcomes. Multivariable logistic and Cox regression analyses were performed to assess associations between ER status, treatment characteristics, pCR, and clinical outcomes. Propensity score matching (PSM) was used as a sensitivity analysis to compare survival outcomes between ER-0 and ER-low tumors. Results Among 1,266 patients, 1,008 had ER-0 and 258 had ER-low tumors. ER-low tumors had a similar likelihood of achieving pCR compared with ER-0 tumors after multivariable adjustment (OR = 0.95, 95% CI: 0.71–1.27; P = 0.726). Platinum-based neoadjuvant chemotherapy was associated with higher odds of pCR in the overall cohort (OR = 1.67, 95% CI: 1.31–2.13; P < 0.001), but not among patients with ER-low tumors (adjusted OR = 1.69, 95% CI: 0.90–3.19; P = 0.104). After a median follow-up of 38 months, DFS and BCSS were comparable between ER-0 and ER-low tumors, both before and after PSM. ER-low status was not independently associated with DFS (adjusted HR = 1.27, 95% CI: 0.88–1.83; P = 0.198) or BCSS (adjusted HR = 1.58, 95% CI: 0.93–2.70; P = 0.090). Platinum-based chemotherapy was not independently associated with improved survival. In contrast, pCR was associated with improved DFS and BCSS in both ER-0 and ER-low tumors, and remained independently prognostic for both outcomes among patients with ER-low tumors. Conclusion ER-low and ER-0 tumors showed comparable treatment response and short-term survival outcomes, while pathologic response remained prognostic in ER-low breast cancer.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-20
DOI
https://doi.org/10.3389/fonc.2026.1992334
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment response and survival outcomes of ER-low versus ER-0 HER2-negative breast cancer after neoadjuvant chemotherapy: a multicenter real-world study

Junyi Shen, Songping Lin, Weibin Lian, Tianzi Hong et al.
2 links
Frontiers in Oncology
Breast Cancer Treatment Studies
article

Treatment response and survival outcomes of ER-low versus ER-0 HER2-negative breast cancer after neoadjuvant chemotherapy: a multicenter real-world study

Junyi Shen, Songping Lin, Weibin Lian, Tianzi Hong, Qingwei Wang
article en

Abstract

Background The clinical significance of ER-low tumors compared with ER-0 tumors in HER2-negative breast cancer remains poorly defined, particularly regarding response to neoadjuvant chemotherapy and survival outcomes. This study aimed to compare the clinical characteristics, treatment response, and survival outcomes between ER-low and ER-0 tumors in a real-world multicenter cohort. Methods We conducted a multicenter retrospective cohort study of patients with HER2-negative breast cancer who received neoadjuvant chemotherapy. Patients were categorized according to ER expression as ER-0 or ER-low (1–10%). The primary endpoint was pCR, while disease-free survival (DFS) and breast cancer-specific survival (BCSS) were evaluated as survival outcomes. Multivariable logistic and Cox regression analyses were performed to assess associations between ER status, treatment characteristics, pCR, and clinical outcomes. Propensity score matching (PSM) was used as a sensitivity analysis to compare survival outcomes between ER-0 and ER-low tumors. Results Among 1,266 patients, 1,008 had ER-0 and 258 had ER-low tumors. ER-low tumors had a similar likelihood of achieving pCR compared with ER-0 tumors after multivariable adjustment (OR = 0.95, 95% CI: 0.71–1.27; P = 0.726). Platinum-based neoadjuvant chemotherapy was associated with higher odds of pCR in the overall cohort (OR = 1.67, 95% CI: 1.31–2.13; P < 0.001), but not among patients with ER-low tumors (adjusted OR = 1.69, 95% CI: 0.90–3.19; P = 0.104). After a median follow-up of 38 months, DFS and BCSS were comparable between ER-0 and ER-low tumors, both before and after PSM. ER-low status was not independently associated with DFS (adjusted HR = 1.27, 95% CI: 0.88–1.83; P = 0.198) or BCSS (adjusted HR = 1.58, 95% CI: 0.93–2.70; P = 0.090). Platinum-based chemotherapy was not independently associated with improved survival. In contrast, pCR was associated with improved DFS and BCSS in both ER-0 and ER-low tumors, and remained independently prognostic for both outcomes among patients with ER-low tumors. Conclusion ER-low and ER-0 tumors showed comparable treatment response and short-term survival outcomes, while pathologic response remained prognostic in ER-low breast cancer.

Frontiers in OncologyVol. 16
Fujian Medical University (CN), Shanghai Sixth People's Hospital (CN)
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon